Medpace Holdings Inc
Research Medpace Holdings Inc (MEDP) on Bullrun: valuation model: 12.9% overvalued, market cap USD 17.04B, P/E 35.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMEDP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal12.9% overvalued
- Market capUSD 17.04B
- P/E35.9
- Financial periodQ2 2026
- RevenueUSD 707.33M
- Net incomeUSD 121.36M
- Free cash flowUSD 138.10M
- Gross margin28.5%
Valuation Snapshot
Bullrun's latest valuation model marks Medpace Holdings Inc as 12.9% overvalued; latest market cap is USD 17.04B; P/E is 35.9.
Peer valuation comparison
Latest P/E is 35.9x versus a Healthcare sector median of 24.61x (45.9% above).
Latest P/E is 35.9x versus a United States median of 23.85x (50.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.53B | USD 451.12M | USD 681.87M | 30.1% | 15.28 | USD 497.05M | USD 113.64M | USD 459.07M |
| FY2024 | USD 2.11B | USD 404.39M | USD 572.27M | 31.1% | 12.63 | USD 669.44M | USD 126.23M | USD 825.55M |
| FY2023 | USD 1.89B | USD 282.81M | USD 396.73M | 27.8% | 8.88 | USD 245.45M | USD 0 | USD 558.95M |
| FY2022 | USD 1.46B | USD 245.37M | USD 351.17M | 29.6% | 7.28 | USD 28.27M | USD 50.00M | USD 386.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 17.04B | 35.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.93B | 36.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.18B | 26.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.41B | 35.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 6.61B | 32.6 | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.84B | 45.2 | n/a | n/a |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries;
ETFs that hold Medpace Holdings Inc
Medpace Holdings Inc is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.50% | 0.40% |
| L&G Healthcare Technology & Innovation ETF USD Acc | 2.12% | 0.49% |
| Robeco NextGen Global Small-Cap Equity UCITS ETF USD Acc | 0.64% | 0.50% |
| Franklin ClearBridge US Smaller Companies UCITS ETF USD Acc | 1.91% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Medpace Holdings Inc overvalued or undervalued?
Bullrun's valuation model currently marks Medpace Holdings Inc as 12.9% overvalued.
What is Medpace Holdings Inc's market cap?
Medpace Holdings Inc's market capitalization is USD 17.04B.
What is Medpace Holdings Inc's P/E ratio?
Medpace Holdings Inc's price-to-earnings (P/E) ratio is 35.9.
What does Medpace Holdings Inc do?
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.